You are here: Industry Insights > GOCOVRI

News List

Adamas Completes Acquisition of OSMOLEX ER americanpharmaceuticalreview
January 14, 2021
Adamas Pharmaceuticals announced the closing of the settlement of patent litigation with Osmotica Pharmaceutical, a subsidiary of Osmotica Pharmaceuticals and completes the acquisition of the global rights to OSMOLEX ER®.
Adamas Announces FDA Filing Acceptance of sNDA to Modify Indication Statement for GOCOVRI americanpharmaceuticalreview
June 16, 2020
Adamas Pharmaceuticals announced its supplemental New Drug Application (sNDA) for GOCOVRI as a treatment for OFF episodes in Parkinson’s disease (PD) patients receiving levodopa-based therapy ...
Adamas Announces Patent for GOCOVRI in Parkinson’s Disease americanpharmaceuticalreview
May 19, 2020
Adamas Pharmaceuticals has been issued a new patent (no. 10,646,456) by the United States Patent and Trademark Office (USPTO) that covers GOCOVRI® (amantadine) extended release capsules.
Adamas Announces Settlement of Patent Litigation with Sandoz americanpharmaceuticalreview
January 03, 2020
Adamas has entered into a Settlement Agreement with Sandoz resolving its ongoing litigation concerning Sandoz’s Abbreviated New Drug Application (ANDA) seeking approval by ...